Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

IMMP

Immutep Limited ADR

Dec 10 • 04:00PM ET

2.12

Dollar change -0.06
Percentage change -2.75	%

Healthcare • Biotechnology • Australia • NASD

Peers: VRTX GILD REGN BMRN SRPT BIIB INCY ALNY IONS NBIX

| Held by: IBB APIE

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.23	Insider Own	0.84%	Shs Outstand	145.26M	Perf Week	4.95%
Market Cap	308.52M	Forward P/E	-	EPS next Y	-0.36	Insider Trans	0.00%	Shs Float	144.30M	Perf Month	14.29%
Income	-27.99M	PEG	-	EPS next Q	-0.14	Inst Own	2.02%	Short Float	3.56%	Perf Quarter	-18.15%
Sales	0.00M	P/S	-	EPS this Y	7.23%	Inst Trans	-	Short Ratio	45.18	Perf Half Y	-21.77%
Book/sh	0.87	P/B	2.43	EPS next Y	-58.52%	ROA	-24.05%	Short Interest	5.13M	Perf Year	2.91%
Cash/sh	0.83	P/C	2.54	EPS next 5Y	-	ROE	-25.75%	52W Range	1.66 - 3.34	Perf YTD	-11.67%
Dividend Est.	-	P/FCF	-	EPS past 5Y	9.98%	ROI	-21.96%	52W High	-36.43%	Beta	2.22
Dividend TTM	-	Quick Ratio	18.25	Sales past 5Y	944.09%	Gross Margin	-	52W Low	27.71%	ATR (14)	0.12
Dividend Ex-Date	-	Current Ratio	18.25	EPS Y/Y TTM	21.49%	Oper. Margin	-	RSI (14)	56.74	Volatility	5.82% 5.82%
Employees	-	Debt/Eq	0.01	Sales Y/Y TTM	-100.00%	Profit Margin	-	Recom	1.43	Target Price	7.60
Option/Short	Yes / Yes	LT Debt/Eq	0.01	EPS Q/Q	17.69%	Payout	-	Rel Volume	0.97	Prev Close	2.18
Sales Surprise	-34.63%	EPS Surprise	3.11%	Sales Q/Q	-	Earnings	Aug 29 AMC	Avg Volume	113.62K	Price	2.12
SMA20	6.01%	SMA50	7.09%	SMA200	-8.87%	Trades		Volume	109,898	Change	-2.75%

Date	Action	Analyst	Rating Change	Price Target Change
May-17-24	Initiated	CapitalOne	Overweight	$10
Aug-03-23	Initiated	Robert W. Baird	Outperform	$7
Aug-03-21	Initiated	Ladenburg Thalmann	Buy	$8.30
Jul-16-21	Resumed	Maxim Group	Buy	$8
Sep-28-18	Initiated	B. Riley FBR	Buy	$7.75
Feb-15-18	Reiterated	Maxim Group	Buy	$7 → $5

Dec-10-24 08:00AM	Immutep Announces Initiation of TACTI-004 Phase III Trial in First Line Non-Small Cell Lung Cancer (GlobeNewswire)
Nov-14-24 08:15AM	Immutep's Efti Shows Excellent Survival Data from INSIGHT-003 Trial in Non-Small Cell Lung Cancer (GlobeNewswire) +11.76%
08:00AM	Positive Data from Phase II Trial in Soft Tissue Sarcoma Presented at CTOS 2024 Annual Meeting (GlobeNewswire)
Oct-29-24 08:00AM	Immutep Quarterly Activities Report Q1 FY25 (GlobeNewswire)
Oct-28-24 08:00AM	Immutep to Present New Phase IIb Data in PD-L1 Negative (CPS (GlobeNewswire)
08:00AM	Loading…
Oct-17-24 08:00AM	Immutep Announces First-in-Human Phase I Study of IMP761 Progresses to Dose Escalation Portion of Trial (GlobeNewswire)
Oct-10-24 08:00AM	Immutep to Participate in the 2024 Maxim Healthcare Virtual Summit (GlobeNewswire)
Oct-04-24 06:12AM	Immutep concludes participant enrolment in Phase II breast cancer trial (Clinical Trials Arena)
Oct-03-24 08:00AM	Immutep Completes Patient Enrolment in Randomised Phase II of AIPAC-003 Trial in Metastatic Breast Cancer (GlobeNewswire)
Sep-24-24 08:00AM	Immutep Receives A$3.6 million R&D Tax Incentive from French Government (GlobeNewswire)
Sep-18-24 08:00AM	New Data to be Presented from EFTISARC-NEO Phase II Evaluating Novel Triple Combination including Immutep's Efti in Soft Tissue Sarcoma (GlobeNewswire)
Sep-16-24 08:00AM	Immutep's Efti in Combination with MSD's KEYTRUDA Leads to Positive Efficacy with Favourable Safety in First Line Head and Neck Cancer (GlobeNewswire) -12.50%
Aug-20-24 08:00AM	Immutep Announces Late-Breaking Abstract in Head & Neck Cancer Selected for Oral Presentation at ESMO Congress 2024 (GlobeNewswire)
Aug-14-24 08:00AM	Immutep Announces First Participant Dosed in Phase I Study of IMP761, a First in Class Agonist LAG-3 Antibody (GlobeNewswire) +8.54%
Aug-07-24 08:00AM	Immutep to Participate in Upcoming Investor Conferences (GlobeNewswire)
08:00AM	Loading…
Jul-31-24 08:00AM	Immutep Quarterly Activities Report Q4 FY24 (GlobeNewswire)
Jul-22-24 08:00AM	Immutep Announces Successful Meeting with FDA on Phase III Design in Non-Small Cell Lung Cancer (GlobeNewswire)
Jul-17-24 08:00AM	Immutep Receives Regulatory Clearance for Phase I Study of First-in-Class LAG-3 Agonist Antibody Designed to Treat Autoimmune Diseases (GlobeNewswire)
Jul-15-24 08:39AM	Immutep (IMMP) Up as Combo Therapy Meets Carcinoma Study Goals (Zacks) -11.69%
Jul-12-24 09:15AM	Immutep tries to regain pep as cancer subgroup data show path forward with a long list of caveats (FierceBiotech.com) +14.93%
07:41AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace)
Jul-11-24 06:40PM	Immutep Reports Positive Results in First Line Head and Neck Squamous Cell Carcinoma Patients with Negative PD-L1 Expression (GlobeNewswire)
Jul-03-24 08:00AM	Immutep Announces Details for Oral Presentation at ESMO Virtual Plenary Session and Webcast to Discuss Clinical Results (GlobeNewswire) +5.32%
Jun-27-24 07:34AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday (InvestorPlace) -32.49%
Jun-25-24 08:00AM	Immutep Signs Exclusive License Agreement with Cardiff University for Next Generation Anti-LAG-3 Molecules for Cancer (GlobeNewswire)
Jun-05-24 06:00AM	Immutep successfully completes institutional placement and institutional component of entitlement offer (GlobeNewswire) -12.08%
Jun-02-24 08:38PM	Immutep Announces Clinical Collaboration with MSD to Evaluate Efti in Combination with KEYTRUDA (pembrolizumab) in Pivotal Phase III Trial (GlobeNewswire)
May-15-24 08:00AM	Immutep Presents Data from Safety Lead-in Phase of AIPAC-003 at ESMO Breast 2024 (GlobeNewswire)
May-02-24 08:00AM	Positive Initial Clinical Data Reported from Immutep's Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma (GlobeNewswire)
Apr-29-24 08:00AM	Immutep Quarterly Activities Report Q3 FY24 (GlobeNewswire)
08:00AM	Loading…
Apr-24-24 08:00AM	Immutep Announces Positive Preliminary Topline Results from TACTI-003 Cohort B (GlobeNewswire)
Apr-18-24 08:00AM	Immutep Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP761 (GlobeNewswire)
Apr-17-24 08:00AM	Immutep Receives Positive Feedback from the Spanish Medicines Agency for Upcoming TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer (GlobeNewswire)
Mar-24-24 07:55AM	11 Best ASX Stocks To Buy Now (Insider Monkey)
Mar-05-24 08:00AM	Immutep Announces First Clinical Data from 90mg Dosing of Efti (GlobeNewswire) +11.06%
Feb-05-24 03:11AM	10 Best Australian Stocks To Buy (Insider Monkey)
Jan-30-24 08:00AM	Immutep Quarterly Activities Report Q2 FY24 (GlobeNewswire)
Jan-04-24 08:00AM	First Patient Dosed in Trial Evaluating Efti and the Anti-PD-L1 Therapy BAVENCIO in Metastatic Urothelial Cancer (GlobeNewswire)
Dec-21-23 08:00AM	Immutep Receives Constructive Regulatory Feedback on TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer (GlobeNewswire)
Dec-07-23 08:00AM	Immutep Receives A$2.6 million R&D Tax Incentive from French Government (GlobeNewswire)
Nov-22-23 08:00AM	Immutep Announces Site Expansion for INSIGHT-003 Phase I Trial (GlobeNewswire)
Nov-09-23 08:00AM	Immutep Completes Enrollment in TACTI-003 Phase IIb Trial of Efti and KEYTRUDA in First Line Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma (GlobeNewswire)
Nov-06-23 08:00AM	Immutep Announces Completion of the Safety Lead-In and Opening of the Randomized Phase II of the AIPAC-003 Phase II/III Trial in Metastatic Breast Cancer (GlobeNewswire)
Nov-03-23 12:00PM	Immutep Announces New Biomarker Data from TACTI-002 Phase II in First Line Non-Small Cell Lung Cancer (GlobeNewswire)
Nov-02-23 08:00AM	Immutep to Participate in November Investor Events (GlobeNewswire)
Oct-31-23 08:00AM	Immutep Quarterly Activities Report Q1 FY24 (GlobeNewswire)
Oct-25-23 08:00AM	Immutep receives ~A$1.13 million R&D Tax Incentive (GlobeNewswire)
Oct-24-23 08:00AM	Immutep Reports Promising Clinical Data from INSIGHT-003 Trial at ESMO Congress 2023 (GlobeNewswire) -7.39%
Oct-23-23 08:00AM	Immutep's Efti in Combination with KEYTRUDA Generates Excellent Overall Survival Benefit in Patients with Metastatic Non-Small Cell Lung Cancer (GlobeNewswire)
Oct-16-23 08:00AM	Immutep Announces Publication of Abstracts at ESMO Congress 2023 (GlobeNewswire)
Oct-03-23 08:00AM	Immutep Announces Abstract Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting (GlobeNewswire)
Sep-21-23 08:00AM	Commercial Manufacturing of Eftilagimod Alpha at 2000L Scale Granted Authorization for Clinical Trial Use (GlobeNewswire)
Sep-05-23 09:00AM	Immutep to Participate in September Investor Conferences (GlobeNewswire)
Aug-03-23 10:03AM	Qualcomm downgraded, Wingstop upgraded: Wall Street's top analyst calls (The Fly)
Aug-01-23 08:00AM	Immutep Receives Positive Scientific Advice from European Medicines Agency (GlobeNewswire)
Jul-31-23 08:00AM	Immutep to Present Overall Survival Data in 1st Line Non-Small Cell Lung Cancer Accepted for Oral Presentation at ESMO Congress 2023 (GlobeNewswire)
08:00AM	Immutep Quarterly Activities Report Q4 FY23 (GlobeNewswire)
Jul-28-23 08:00AM	First Patient Dosed in Chemotherapy-Free Triple Combination Phase II Trial Targeting Soft Tissue Sarcoma (GlobeNewswire)
Jul-06-23 05:57PM	With 49% stake, Immutep Limited (ASX:IMM) seems to have captured institutional investors' interest (Simply Wall St.)
Jun-27-23 08:00AM	Immutep Secures Third United States Patent for Eftilagimod Alpha in Combination with a PD-1 Pathway Inhibitor (GlobeNewswire)
08:00AM	Immutep Completes A$80 Million Capital Raise (GlobeNewswire)
Jun-20-23 08:00AM	Immutep Granted United States Patent for IMP761, a First-in-Class Agonist Antibody Targeting LAG-3 (GlobeNewswire)
Jun-14-23 07:01PM	3 Best Penny Stocks Under $3 to Buy in June (InvestorPlace)
Jun-09-23 05:21PM	The 12% return this week takes Immutep's (ASX:IMM) shareholders three-year gains to 96% (Simply Wall St.)
Jun-07-23 08:00AM	Immutep to Participate at the Jefferies Healthcare Conference (GlobeNewswire)
Jun-05-23 08:00AM	Immutep Reports Final Positive Data in 2nd Line Head and Neck Squamous Cell Carcinoma at ASCO 2023 Annual Meeting (GlobeNewswire)
Jun-02-23 08:00AM	Immutep Successfully Completes Institutional Placement and Institutional Component of its Entitlement Offer (GlobeNewswire)
May-29-23 08:00AM	Immutep Selects Charles River Laboratories for IMP761s GLP Toxicology Study (GlobeNewswire)
May-26-23 08:00AM	Immutep Announces Publication of Abstracts for ASCO 2023 Annual Meeting (GlobeNewswire) -7.39%
May-25-23 08:00AM	Immutep Doses First Patient in AIPAC-003 Phase II/III Trial for Metastatic Breast Cancer (GlobeNewswire) -6.12%
May-24-23 08:00AM	Immutep Announces Promising New Clinical Data from Triple Combination Therapy in INSIGHT-003 Trial (GlobeNewswire) +6.52%
May-17-23 08:00AM	Immuteps Efti in Combination with Pembrolizumab Achieves Excellent Initial Overall Survival Benefit in 1st Line Non-Small Cell Lung Cancer (GlobeNewswire) +64.78%
May-16-23 08:00AM	Immutep Receives Positive Feedback from FDA on Late-Stage Clinical Development of Eftilagimod Alpha in Non-Small Cell Lung Cancer (GlobeNewswire)
May-09-23 08:00AM	Immutep to Participate in the JMP Securities Life Sciences Conference (GlobeNewswire)
May-02-23 08:00AM	Immutep Announces KOL Event Focused on Eftilagimod Alpha in Non-Small Cell Lung Cancer and Head & Neck Squamous Cell Carcinoma (GlobeNewswire)
May-01-23 08:00AM	Immutep Receives Approval to Initiate INSIGHT-005 Trial Evaluating Eftilagimod Alpha and Anti-PD-L1 Therapy BAVENCIO® (GlobeNewswire)
Apr-27-23 08:00AM	Immutep Quarterly Activities Report (GlobeNewswire)
Apr-26-23 10:00AM	Immutep Announces Presentation of New TACTI-002 Data at the 2023 ASCO Annual Meeting (GlobeNewswire)
08:00AM	Immutep Appoints Dr. Florian Vogl as Chief Medical Officer (GlobeNewswire)
Apr-17-23 09:00AM	Immutep Announces Initiation of Investigator-Initiated Phase II Trial in Soft Tissue Sarcoma in Neoadjuvant Setting (GlobeNewswire)
Apr-12-23 07:55PM	7 Best Penny Stocks Under $3 to Buy in April (InvestorPlace)
Mar-31-23 08:00AM	Immutep Announces Positive Final Data in 2nd Line Metastatic NSCLC Patients Refractory to Anti-PD-(L)1 Therapy at European Lung Cancer Congress 2023 (GlobeNewswire)
Mar-30-23 08:00AM	Immutep Announces Expansion of Triple Combination Therapy in 1st Line Non-Small Cell Lung Cancer (GlobeNewswire)
Mar-23-23 08:00AM	Immutep Announces Abstract Accepted for Mini Oral Presentation at ESMOs European Lung Cancer Congress 2023 (GlobeNewswire)
Mar-14-23 08:00AM	Immutep Announces Initiation of Phase II/III Trial for Eftilagimod Alpha plus Paclitaxel in Metastatic Breast Cancer (GlobeNewswire) +5.12%
Feb-06-23 08:00AM	Immutep Reaches Enrolment Target for INSIGHT-003 Trial in 1st Line NSCLC (GlobeNewswire)
Jan-30-23 08:00AM	Immutep Quarterly Activities Report (GlobeNewswire)
Jan-04-23 08:00AM	Immutep Achieves 50% Enrollment Milestone in Randomised Phase IIb TACTI-003 Trial for First Line Head & Neck Cancer (GlobeNewswire)
Dec-23-22 08:00AM	Immutep Announces Successful Meeting with the FDA on Eftilagimod Alpha plus Chemotherapy for the Treatment of Metastatic Breast Cancer (GlobeNewswire) +5.82%
Dec-08-22 08:00AM	Immutep Successfully Achieves Commercial Scale in Manufacturing of Eftilagimod Alpha (GlobeNewswire) +5.83%
Dec-06-22 08:00AM	Immutep Announces GMP Manufacturing Process Developed for IMP761, a First-in-Class LAG-3 Agonist for Autoimmune Disease (GlobeNewswire)
Dec-02-22 08:00AM	Immutep to Participate in The JMP Securities Hematology and Oncology Summit (GlobeNewswire)
Nov-29-22 08:00AM	Immutep Enters into Second Clinical Trial Collaboration Agreement with Merck KGaA, Darmstadt, Germany, and Pfizer for New Combination Study of its First-in-Class LAG-3 Candidate, Eftilagimod Alpha, and Avelumab to Treat Urothelial Cancer (GlobeNewswire) +5.08%
Nov-16-22 03:14PM	Here's Why Immutep Limited's (ASX:IMM) CEO Compensation Is The Least Of Shareholders' Concerns (Simply Wall St.) -5.96%
Nov-14-22 08:00AM	Immutep Receives Australian R&D Tax Incentive (GlobeNewswire)
Nov-10-22 11:10AM	Immutep Announces Compelling Clinical Results from Phase II Trial Utilizing its First-in-Class Soluble LAG-3 Protein, Eftilagimod Alpha, in 1st Line NSCLC at SITC 2022 Annual Meeting (GlobeNewswire) +7.73%
09:00AM	Immutep Announces Promising Initial Clinical Data from INSIGHT-003 at SITC 2022 (GlobeNewswire)
Nov-09-22 08:00AM	Immutep Granted New Patents in Japan and South Korea for First-in-Class LAG-3 Candidate, Eftilagimod Alpha in Chemo-Immunotherapy Combination (GlobeNewswire) -7.62%
Nov-04-22 08:00AM	Immutep Announces Abstract Highlighting Eftilagimod Alpha Selected for SITC 2022 Annual Meeting Press Conference (GlobeNewswire) +9.29%
Nov-02-22 08:00AM	Immutep Late-Breaking Abstract Accepted for Oral Presentation on First-in-Class LAG-3 Therapeutic Eftilagimod Alpha at the Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting (GlobeNewswire)

Immutep Ltd. is a clinical stage biotechnology company, which engages in the development of LAG-3 related immunotherapeutic products for cancer and autoimmune diseases. Its products include eftilagimod alpha (IMP321), IMP761, leramilimab (IMP701), and GSK'781 (IMP731). The company was founded on May 21, 1987 and is headquartered in Sydney, Australia.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

IMMP

Immutep Limited ADR

Upgrade your FINVIZ experience